COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences:

Jefferies 14th Annual Global Healthcare Conference

Fireside Chat Date and Time: Tuesday, November 14, 2023, at 9:30 a.m. GMT

Piper Sandler 35th Annual Healthcare Conference

Fireside Chat Date and Time: Tuesday, November 28, 2023, at 4:00 p.m. ET

The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contact:

Christopher James, M.D.

Vice President, Investor Relations

Media Contact:

Marissa Samuels

Vice President, Corporate Communications





EN
08/11/2023

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 11,659 shares at 34.363USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

COLL COLLEGIUM PHARMACEUTICAL INC.
21h / 18m 21h / 18m 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 O...

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to...

August 7, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Second Quarter 2025 Financial Results on August 7,...

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q2 2025 Earnings Call.” An audio webc...

July 24, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces $150 Million Share Repurchase Program

Collegium Announces $150 Million Share Repurchase Program STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026. This program replaces a previous $150 million share repurchase program authorized in January 2024 which expired on June 30, 2025, and had $65 million remaining under the progr...

July 7, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET Jefferies Global Healthcare ConferencePresentation: Thursday, June 5, 2025, at 1:25 p.m. ET The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast wi...

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch